Cleo Diagnostics Ltd

Equities

COV

AU0000288045

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 10:51:37 2024-05-19 pm EDT 5-day change 1st Jan Change
0.17 AUD -5.56% Intraday chart for Cleo Diagnostics Ltd 0.00% -2.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials MT
CLEO Taps HcFocus for US Market Entry MT
Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology MT
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 1-DEC-2023. CI
162,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-NOV-2023. CI
Cleo Diagnostics Confirms Efficacy of Ovarian Cancer Test from Validation Study; Shares Surge 21% MT
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 4-NOV-2023. CI
425,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-OCT-2023. CI
75,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-OCT-2023. CI
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 18-OCT-2023. CI
100,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 13-OCT-2023. CI
Cleo Diagnostics Advances Development of Cancer Test Kit MT
CLEO Diagnostics’ Chief Scientific Officer Move to Full-Time Arrangement MT
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-SEP-2023. CI
125,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI
37,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-SEP-2023. CI
CLEO Diagnostics Secures US Patent for Ovarian Cancer Biomarker Testing MT
Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million. CI
Cleo Diagnostics Ltd has filed an IPO in the amount of AUD 12 million. CI
Chart Cleo Diagnostics Ltd
More charts
Cleo Diagnostics Ltd is an Australia-based medical diagnostics company. The Company is focussed on the development of non-invasive blood based In vitro diagnostics (IVD) tests to detect the presence, and recurrence, of ovarian cancer. The Company has developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant. Recurrence Test is a post-surgical test to identify whether a cancer is recurring following surgical removal and chemotherapy of a primary tumour. Screening Test is a screening test to identify early-stage ovarian cancer in women who do not present any symptoms consistent with ovarian cancer. The Company also offers the CLEO Test Kit, which is designed to detect a novel protein biomarker, CXCL10 in the blood.
More about the company
  1. Stock Market
  2. Equities
  3. COV Stock
  4. News Cleo Diagnostics Ltd
  5. Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW